GZMM Antibody (monoclonal) (M03)
Mouse monoclonal antibody raised against a partial recombinant GZMM.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | P51124 |
Other Accession | NM_005317 |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Isotype | IgG2a Kappa |
Clone Names | 4D11 |
Calculated MW | 27545 Da |
Gene ID | 3004 |
---|---|
Other Names | Granzyme M, 3421-, Met-1 serine protease, Hu-Met-1, Met-ase, Natural killer cell granular protease, GZMM, MET1 |
Target/Specificity | GZMM (NP_005308, 85 a.a. ~ 193 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | GZMM Antibody (monoclonal) (M03) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Human natural killer (NK) cells and activated lymphocytes express and store a distinct subset of neutral serine proteases together with proteoglycans and other immune effector molecules in large cytoplasmic granules. These serine proteases are collectively termed granzymes and include 4 distinct gene products: granzyme A, granzyme B, granzyme H, and Met-ase, also known as granzyme M.
References
1.Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.Schiffer S, Letzian S, Jost E, Mladenov R, Hristodorov D, Huhn M, Fischer R, Barth S, Thepen TCancer Lett. 2013 Aug 22. pii: S0304-3835(13)00578-8. doi: 10.1016/j.canlet.2013.08.005.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.